These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 31499027

  • 1. Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis.
    Porter CM, Haffner MC, Kulac I, Maynard JP, Baena-Del Valle JA, Isaacs WB, Yegnasubramanian S, De Marzo AM, Sfanos KS.
    Am J Pathol; 2019 Nov; 189(11):2311-2322. PubMed ID: 31499027
    [Abstract] [Full Text] [Related]

  • 2. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
    Kang GH, Lee S, Lee HJ, Hwang KS.
    J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
    [Abstract] [Full Text] [Related]

  • 3. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm.
    Cho NY, Kim JH, Moon KC, Kang GH.
    Virchows Arch; 2009 Jan; 454(1):17-23. PubMed ID: 19048291
    [Abstract] [Full Text] [Related]

  • 4. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP, Harya NS, Hutzley J, Bacich DJ, Monzon FA, Chandran U, Dhir R, O'Keefe DS.
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
    [Abstract] [Full Text] [Related]

  • 5. Silencing of Lactotransferrin expression by methylation in prostate cancer progression.
    Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Bañez L, Nau M, Ravindranath L, Kim KH, Mohammed A, Chen Y, Ehrich M, Srikantan V, Sesterhenn IA, McLeod D, Vahey M, Petrovics G, Dobi A, Srivastava S.
    Cancer Biol Ther; 2007 Jul; 6(7):1088-95. PubMed ID: 17568188
    [Abstract] [Full Text] [Related]

  • 6. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
    Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH.
    J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
    Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP.
    Tumour Biol; 2005 Feb; 26(6):324-36. PubMed ID: 16254462
    [Abstract] [Full Text] [Related]

  • 9. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.
    Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG.
    Cancer Res; 2008 Nov 01; 68(21):8954-67. PubMed ID: 18974140
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hypermethylation of the caveolin-1 gene promoter in prostate cancer.
    Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR.
    Prostate; 2001 Feb 15; 46(3):249-56. PubMed ID: 11170154
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
    Sørensen KD, Borre M, Ørntoft TF, Dyrskjøt L, Tørring N.
    Int J Cancer; 2008 Feb 01; 122(3):509-19. PubMed ID: 17943724
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Aberrant Hypermethylation-Mediated Suppression of PYCARD Is Extremely Frequent in Prostate Cancer with Gleason Score ≥ 7.
    Miyauchi T, Takahashi M, Mitsuzuka K, Saiki Y, Okubo T, Vertino PM, Goto A, Arai Y, Horii A, Fukushige S.
    Dis Markers; 2021 Feb 01; 2021():8858905. PubMed ID: 33628338
    [Abstract] [Full Text] [Related]

  • 18. Epigenetically Silenced Candidate Tumor Suppressor Genes in Prostate Cancer: Identified by Modeling Methylation Stratification and Applied to Progression Prediction.
    Zhang W, Flemington EK, Deng HW, Zhang K.
    Cancer Epidemiol Biomarkers Prev; 2019 Jan 01; 28(1):198-207. PubMed ID: 30262601
    [Abstract] [Full Text] [Related]

  • 19. Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma.
    Yi HM, Li H, Peng D, Zhang HJ, Wang L, Zhao M, Yao KT, Ren CP.
    Oncol Res; 2006 Jan 01; 16(6):261-72. PubMed ID: 17476971
    [Abstract] [Full Text] [Related]

  • 20. Re-expression of Lactotransferrin, a candidate tumor suppressor inactivated by promoter hypermethylation, impairs the malignance of oral squamous cell carcinoma cells.
    Zhang J, Ling T, Wu H, Wang K.
    J Oral Pathol Med; 2015 Sep 01; 44(8):578-84. PubMed ID: 25370482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.